Technology Transfer Process
High Beam Software Artificial Intelligence Laboratory at Macau University of Science and Technology
The High Beam Software Artificial Intelligence Laboratory was established on March 22, 2017, in the Macau University of Science and Technology. The laboratory fully utilizes the academic resource advantages of the University in various branches of artificial intelligence, and the market and industrialization platform advantage of Farlight Software in energy, power and other large central enterprises' group production, management information, and smart city construction.
The laboratory promotes the integration and application of artificial intelligence technology with big data, Internet of Things, mobile interconnection, and other cutting-edge technologies. It explores human-computer interaction, environment perception, data collection, intelligent decision control and other fields of innovation and expansion. It focuses on technology to overcome barriers, accelerate the transformation of scientific and technological achievements, and help industries to develop their business. We aim to explore the innovation and expansion of human-computer interaction to transform the industry and upgrade intelligent manufacturing.
Collaborative Laboratory for Intelligent Science and Systems
The Macao Institute of Systems Engineering and IKAS Industry set up the Collaborative Laboratory for Intelligent Science and Systems in 2020. Dedicated to semiconductor manufacturing systems, it aims to improve their productivity and wafer quality by using novel methods and technologies, such as artificial intelligence, operation research, discrete event systems theory, and internet of things.
Developed by the research team led by Chair Prof. Liu Liang, an academician of the Chinese Academy of Engineering. Zhengqing Fengtongning is a drug from which a series of products for the treatment of rheumatoid arthritis have been developed jointly with the Hunan Zhengqing Pharmaceutical Group. The research results were awarded the State Scientific and Technological Progress Award with M.U.S.T. as the first completer, marking the first time that Macao and Hong Kong have won a national science and technology award in the research of Chinese medicine.
Developed by Chair Prof. Zhu Yizhun’s research team. After more than 10 years of painstaking research, it has been found that the monomer extracted and chemically synthesized from the colloquially known herb Motherwort, or Leonurus cardiaca (also known as SCM-198), has obvious efficacy on hyperlipidemia, atherosclerosis, cerebral apoplexy, and other diseases. Motherwort has been confirmed to have a significant lipid-lowering effect, which can inhibit the inflammation of atherosclerotic plaques and reduce the area of cerebral cortex infarction caused by cerebral ischemia. It sustains a fast and significant effect on the treatment of acute stroke, bringing good news to middle-aged and elderly patients with cardiovascular and cerebrovascular diseases.
At present, the project has applied for patent protection, has obtained the "drug clinical trial approval" issued by the State Drug Administration, and has been approved to conduct clinical research in the United States through the FDA.
Singou Robot Series
Developed by the M.U.S.T. information security research team. Anxintong Technology (Macau) Co., Ltd. is a commercial entity established by the industrialization of the scientific results of the research team. Core products include "Tianji No. 1", "Little Margo No. 1", "Singou Car Robot”, and "Singou One Robot”.
Taxus Chinensis siRNA New Drug Techniques
Developed by Chair Prof. Jiang Zhihong’s research team. Small interfering nucleic acid siRNA drugs are one of the fastest growing new biomedicines today, and new drug candidates can be quickly designed according to the target gene mRNA, but siRNA drugs cannot be designed for diseases with unknown targets. To this end, the team of Professor Jiang Zhihong, director of the State Key Laboratory of Quality Research in Traditional Chinese Medicine of Macau University of Science and Technology, adopted a research strategy that is contrary to the current siRNA drug design, and through the established RNA omics platform, the RNA molecule tRF-T11 with strong cytotoxicity to tumor cells was screened from the southern yew tree, and the proliferation of ovarian cancer was inhibited by the RNAi mechanism. The research was published as a cover article (2022, 27, 718-732) in the world-renowned Cell Press Journal Molecular Therapy-Nucleic Acids (top 10% in the field of medical research and experimentation, impact factor 8.886). This is the world's first original discovery on plant tRNA and its fragments to treat diseases by regulating genes, fully demonstrating M.U.S.T.’s comprehensive strength in the field of medicinal plant RNA research. The research results have been authorized by Chinese, Australian, and American patents, and in 2020, the "Technology Transfer Contract" was signed with Yingkerui (Hong Kong) Innovative Pharmaceutical Co., Ltd., which accomplished the transformation of scientific research achievements of universities. At present, the project is in the preclinical research and development stage, including active sequence optimization, new dosage form research, and activity evaluation. In the future, the two sides will jointly promote the development of the world's first new siRNA drug of plant origin.
KR2 Eye Drops
Developed by Professor Zhang Kang’s research team. This product is a Class 1 innovative drug, the indications are mainly used for the treatment of wet macular degeneration, diabetic retinopathy, iris neovascularization and corneal neovascularization, and other blinding eye diseases.
Professor Zhang Kang obtained a new structure of the active small molecule compound KR2 through a large number of studies, the mechanism of action is to inhibit vegfr2 activity to inhibit the formation of new blood vessels in the eye, and successfully developed it as an eye drop as an non-invasive treatment. According to the preclinical evaluation of the drug in human clinical trials, the drug is safe and has an obvious therapeutic effect, with potential to greatly reduce the treatment cost of patients and alleviate the painful conditions. At present, the drug has 2 international PCT patents and has been authorized by 8 national patents.
The following materials are available in Chinese only.